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ABSTRACT	
BACKGROUND	AND	OBJECTIVES	Coronary	 flow	 velocity	 (CFV)	 and	 coronary	 flow	 velocity	 reserve	 (CFVR)	evaluated	by	transthoracic	ultrasound	is	a	promising	method	to	assess	ischemic	heart	 disease.	 CFVR	 is	 the	 ratio	 between	 CFV	 during	maximal	 hyperemia	 and	baseline.	A	reduced	CFVR	indicates	an	increased	risk	for	cardiovascular	events.	The	 aims	 of	 this	 thesis	 were	 1.	 To	 evaluate	 the	 effect	 of	 nitroglycerine	administration	on	CFV	and	CFVR.	2.	To	investigate	if	CFVR	provides	prognostic	information	about	cardiovascular	events,	in	addition	to	myocardial	scintigraphy,	in	 patients	 with	 suspected	 coronary	 artery	 disease.	 3.	 To	 investigate	 the	relationship	 between	 CFVR	 and	 significant	 coronary	 stenosis.	 4.	 To	 assess	 the	effects	of	ticagrelor	on	CFV	and	dyspnea.		
METHODS	In	study	I,	CFV	and	CFVR	and	coronary	artery	diameter	were	assessed	before	and	after	sublingual	nitroglycerine	administration	in	26	healthy	subjects.	In	study	II,	CFVR	was	measured	in	371	patients	undergoing	scintigraphy	due	to	suspected	coronary	 artery	 disease.	 CFVR	 and	 scintigraphy	 results	 were	 related	 to	cardiovascular	 events	 (cardiovascular	 death,	 myocardial	 infarction,	 acute	revascularization)	during	a	mean	follow-up	of	4.5	years.	In	study	III,	CFVR	and	coronary	angiograms	were	evaluated	in	123	patients	from	study	II.	Study	IV	was	a	 double-blind	 placebo-controlled	 cross-over	 study	 randomizing	 40	 healthy	subjects	to	ticagrelor	or	placebo.	CFV	and	dyspnea	were	assessed	at	baseline	and	during	increasing	doses	of	adenosine.				
RESULTS	Nitroglycerine	 increased	CFVR	due	 to	 a	 reduction	 in	baseline	CFV.	Adenosine-induced	CFV	remained	unchanged.	A	CFVR≤2	was	independently	associated	with	cardiovascular	event	rate	(adjusted	hazard	ratio	3.02	(1.51-6.04,	p=0.002)	and	added	prognostic	information	in	addition	to	scintigraphy.	There	was	a	significant	association	 between	 CFVR	 and	 the	 presence	 of	 coronary	 stenoses.	 Ticagrelor	augmented	CFV	and	dyspnea	during	adenosine	administration.		 	
CONCLUSIONS	Nitroglycerine	 increases	 CFVR	 which	 indicates	 that	 adenosine	 alone	 causes	 a	submaximal	 hyperemia.	 The	 associations	 between	 CFVR	 and	 cardiovascular	events,	 and	 between	 CFVR	 and	 significant	 coronary	 stenosis	 supports	 routine	assessment	with	 CFVR	 in	 patients	with	 suspected	 ischemic	 heart	 disease.	 The	results	indicate	that	adenosine	is	involved	in	the	systemic	effects	of	ticagrelor.	
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1 INTRODUCTION Ischemic	 heart	 disease,	 caused	 by	 atherosclerosis	 in	 the	 coronary	arteries,	 is	 the	main	 killer	 in	 the	western	world	 (1).	 Even	 though	 it	 is	considered	a	 lifestyle	disease,	known	to	increase	with	excessive	eating,	lack	of	exercise	and	the	metabolic	syndrome	(2,	3),	it	is	a	disease	that	has	haunted	mankind	for	thousands	of	years	(4).	
Figure 1. CT-exam of 4000-year old Egyptian mummy. With 
permission from Elsevier Ltd.  
Body	 CT	 scans	 of	 4000-year-old	 mummies	 from	 four	 different	geographical	regions	have	revealed	atherosclerosis,	defined	as	calcified	coronary	 plaques,	 in	 35%	of	 the	mummies	 (5).	 The	 researchers	 found	that	 the	 presence	 of	 atherosclerotic	 plaques	 was	 positively	 correlated	with	 a	 significant	 reduction	 of	 the	 life	 span.	 Mean	 age	 at	 death	 for	individuals	without	atherosclerosis	was	43	years	compared	to	32	years	for	 the	mummies	with	atherosclerosis,	 indicating	 that	 this	disease	was	potentially	lethal	even	before	modern	life.		Ischemic	 heart	 disease	 (IHD)	 includes	 stable	 angina	 pectoris,	 unstable	angina	 pectoris,	 myocardial	 infarction	 (MI)	 —both	 non-ST-elevation	myocardial	infarction	(NSTEMI)	and	ST-elevation	myocardial	infarction	(STEMI)—	and	sudden	cardiac	death	(6).	As	in	most	progressive	diseases,	the	prognosis	is	improved	with	early	detection	(7).	Primary	prevention	
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of	 ischemic	 heart	 disease	 is	 preferable	 over	 secondary	 prevention	 in	order	 to	 keep	 the	 population	 healthy	 and	 event	 free	 (8).	 In	 this	work,	diagnostic	tools	that	are	able	to	diagnose	coronary	atherosclerosis	in	its	early	stages	are	essential.	Unfortunately,	atherosclerosis	is	silent	until	it	has	progressed	to	the	extent	of	limiting	blood	flow.	When	coronary	blood	flow	becomes	limited,	the	patient	develops	symptoms,	the	disease	can	be	diagnosed	 and	 the	 treatment	 started.	By	 then,	 the	majority	 of	 patients	have	already	developed	a	chronic	disease.		
Coronary artery anatomy The	proximal	parts	of	the	coronary	arteries	are	normally	located	on	the	heart’s	 surface	 and	 are	 therefore	 often	 called	 epicardial	 coronary	arteries.	The	 left	and	the	right	coronary	arteries	originate	 in	 the	aortic	root	just	distal	to	the	aortic	valve	leaflets.	The	left	main	coronary	artery	divides	 into	 the	 left	descending	artery	(LAD)	and	the	circumflex	artery	(LCx).	The	small	arteries,	arterioles	and	capillaries	are	often	referred	to	as	the	microvascular	circulation.	Arterial	vessels	are	constructed	of	three	main	layers.	The	outer	layer,	the	
tunica	adventitia,	contains	connective	tissue	and	vasa	vasorum.	The	vasa	vasorum	 are	 the	 internal	 blood	 vessels	 of	 the	 arterial	 wall,	 which	 the	arterial	vessel	is	dependent	on	for	delivery	of	oxygen	and	nutrition	to	the	entire	 arterial	 wall	 (9).	 The	 connective	 tissue	 acts	 as	 a	 supportive	structure	for	the	vessel	wall.	The	middle	 layer,	 the	 tunica	media	 is	 the	 thickest	 layer	 of	 the	 healthy	arterial	wall.	It	is	composed	of	vascular	smooth	muscle	cells,	connective	tissue	and	elastic	fibers.	The	media	is	important	as	its	smooth	muscle	cells	regulate	vessel	diameter,	and	thereby	coronary	blood	flow,	as	a	response	to	different	chemical	and	autonomous	signals	(10).	The	 inner	 layer,	 the	 tunica	 intima,	 is	 involved	 in	 complex	 chemical	processes	 and	 consists	 in	 healthy	 arteries	 of	 endothelial	 cells	 and	 the	internal	elastic	lamina.	The	endothelium	is	the	“mastermind”	of	the	vessel	and	 has	 the	 capacity	 to	 regulate	 blood	 flow	 though	 the	 arterial	
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vasculature	 by	 different	 receptors	 and	 vasoactive	 substances	 that	regulate	vascular	tonus	and	vascular	lumen	size	(10,	11).	
Arterial flow regulation The	 myocardium	 has	 a	 high	 basal	 oxygen	 consumption	 (8-10	 ml	O2/min/100g)	 and	 is	 directly	 dependent	 on	 increased	 blood	 flow	whenever	 cardiac	 activity	 increases	 (12).	 In	 healthy	 vessels,	 active	hyperemia	is	almost	proportional	to	the	increase	in	oxygen	consumption.	Hypoxia	generates	a	reduction	in	arterial	resistance	in	order	to	increase	blood	flow,	and	thereby	oxygen	supply,	to	the	myocardium	(11,	13,	14).	
Nitric oxide (NO) Nitric	 oxide	 (NO)	 is	 a	 powerful	 vasodilator,	 also	 called	 endothelium-derived	relaxing	factor	(EDRF).	The	endothelium	is	able	to	produce	NO	from	 the	 amino	 acid	 L-arginine	 and	 release	 it	 to	 induce	 relaxation	 of	smooth	 muscle	 cells	 in	 the	 tunica	 media	 (15,	 16).	 NO	 production	 is	initiated	 either	 by	 flow-dependent	 mechanisms	 or	 by	 receptor	stimulation.	 The	 flow-mediated	 production	 begins	 when	 vascular	endothelium	 is	 exposed	 to	 shear	 stress	 forces	 (17).	 NO	 is	 also	 anti-thrombotic	 as	 it	 inhibits	 platelet	 aggregation	 and	 has	 an	 anti-inflammatory	effect	as	it	inhibits	leucocyte–endothelial	interactions	(17).		
Prostaglandins Prostaglandins	are	produced	by	almost	all	cells	and	can	be	found	in	all	tissues	 of	 the	 human	 body.	 Prostaglandins	 have	 two	 derivatives,	
prostacyclin	and	thromboxane.	The	vessel	wall	can	produce	prostacyclin,	which	regulates	vessel	wall	contraction	and	prevents	blood	clots.	It	is	an	efficient	vessel	dilatator,	acting	locally	in	the	vessel	where	it	is	produced.	In	 arteries,	 the	 platelets	 produce	 thromboxane	 which	 acts	 as	 a	vasoconstrictor.	 Thromboxane	 also	 induces	 platelet	 aggregation	 and	formation	of	blood	clots	(18).		
Adenosine Adenosine	is	another	powerful	vasodilator.	Adenosine	acts	as	a	metabolic	link	between	oxygen	consumption	and	coronary	blood	flow	(19).	When	
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local	 hypoxia	occurs	 in	 the	myocardium,	 an	 endogenous	production	of	adenosine	starts.	It	regulates	coronary	blood	flow	by	dilating	resistance	vessels	 and	 thereby	 lowering	 the	 peripheral	 vessel	 resistance	 in	 the	coronary	artery	tree	(20).	Both	endogenously	produced	and	exogenously	administered	 adenosine	 is	 rapidly	 deactivated,	 mainly	 by	 uptake	 into	erythrocytes	and	de-amination.			Adenosine,	administered	as	a	continuous	infusion,	is	used	as	a	vasodilator	to	 induce	 hyperemia	 and	 aid	 in	 detecting	 ischemia	 during	echocardiography	 stress	 test	 or	 myocardial	 perfusion	 scintigraphy	(MPS).	 Signs	 of	 ischemia	 are	 wall	 motion	 defects	 during	echocardiography	or	a	perfusion	defect	on	MPS.	Adenosine	may	also	be	used	 therapeutically,	 given	 as	 a	 bolus	 to	 treat	 supraventricular	tachycardia,	as	it	suppresses	the	atrio–ventricular	conduction	(21).	Due	to	adenosine’s	short	half-life,	the	drug	effect	is	easy	to	control	in	a	clinical	setting.	After	the	 infusion	is	stopped,	all	vasodilatory	effects,	as	well	as	side	effects,	of	adenosine	terminate	within	less	than	a	minute.		There	 has	 been	 a	 concern	 about	 a	 coronary	 artery	 steal	 phenomenon	when	adenosine	is	infused.	This	means	that	dilatation	of	healthy	coronary	vessels	 “steals”	 blood	 from	 coronary	 arteries	 with	 narrower	 lumen,	leading	to	alterations	in	the	coronary	circulation.		There	is	however,	no	clear	evidence	that	this	potential	adverse	effect	exists.		
 
Figure 2. Adenosine and caffeine molecule structures. 
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When	exogenous	adenosine	is	administered,	the	side	effects	are	mainly	related	 to	 its	 vasodilator	 effects,	 such	 as	 facial	 flushing,	 headache	 and	hypotension	 (22,	 23).	 Many	 patients	 also	 experience	 a	 sensation	 of	dyspnea	which	is	believed	to	be	caused	by	stimulation	of	receptors	in	the	lungs,	most	likely	mediated	by	vagal	C	fibers	(22,	24).	Methylxanthines,	for	example	caffeine	and	theophylline,	are	competitive	antagonists	 to	 adenosine,	 binding	 to	 the	 same	 purinergic	 receptor.	Therefore,	 a	 minimum	 of	 12	 hours	 abstinence	 from	 drinks	 and	 food	containing	caffeine	is	recommended	when	using	adenosine	in	a	clinical	setting	for	myocardial	perfusion	stress	tests	(25).	
Coronary artery disease Coronary	artery	disease	(CAD)	is	typically	caused	by	atherosclerosis	and	results	 in	 changes	 in	 both	 function	 and	 structure	 of	 the	 vessel.	Atherosclerotic	changes	involve	an	abnormal	deposition	of	lipids	in	the	vessel	 wall,	 leukocyte	 infiltration	 and	 vascular	 inflammation	 (26).	Already	at	early	stages,	endothelial	dysfunction	may	occur	(27,	28).	A	 compromised	 endothelium	 loses	 its	 ability	 to	 produce	 NO	 and	prostacyclin	 (19).	 Subsequently,	 this	 leads	 to	 impaired	 autoregulation	resulting	in	reduced	capacity	to	increase	coronary	flow	during	increased	metabolic	oxygen	demand	due	 to	exercise.	The	 increase	 in	 flow	during	exercise	 is	 referred	 to	 as	 the	 coronary	 flow	 reserve	 (CFR).	 As	 the	atherosclerotic	 disease	 progresses,	 lumen	 narrowing	 plaques	 —stenoses—	 begin	 to	 form,	 further	 limiting	 the	 blood	 flow	 and	 flow	reserve.	Manifest	atherosclerosis	in	the	coronary	arteries	is	the	strongest	predictor	of	cardiovascular	events	of	all	known	biomarkers	(29).		
Mechanisms that limit coronary flow  Coronary	flow	is	mainly	dependent	on	three	major	variables.	Epicardial	artery	lumen	diameter,	regulation	of	the	peripheral	resistance,	and	blood	viscosity.	 When	 the	 lumen	 diameter	 of	 larger	 epicardial	 vessels	 is	affected,	 it	 is	 mainly	 through	 narrowing	 atherosclerotic	 plaques.	 A	general	 thickening	 of	 the	 vessel	 wall	 caused	 by	 vasculitis	 and	 other	
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inflammatory	processes,	resulting	in	lumen	reduction,	also	occurs	but	is	rarer	(30,	31).	Impaired	autoregulation	can	limit	flow	when	endothelial	dysfunction	 prevents	 vasodilatation	 despite	 an	 increased	 metabolic	demand.	High	blood	viscosity	may	limit	blood	flow	through	the	capillaries	thus	increasing	vascular	resistance	(32-34).		
Effects of reduced coronary flow  As	the	atherosclerosis	progresses,	 it	starts	to	limit	coronary	blood	flow	due	to	flow	limiting	stenoses	and/or	dysfunctional	autoregulation	due	to	microvascular	 disease.	 When	 the	 oxygen	 consumption	 exceeds	 the	oxygen	 supply,	 ischemia	 occurs.	 In	 this	 situation,	 when	 metabolic	demand	 is	 not	 met,	 the	 result	 can	 be	 angiogenesis,	 growth	 of	 new	collateral	arteries.	The	collaterals	support	the	arteries	that	are	no	longer	sufficient	 to	 supply	 the	 myocardium	 with	 oxygenated	 blood.	 As	 the	collaterals	develop,	an	increased	blood	flow	can	pass	though	the	vessels	and	the	peripheral	resistance	is	reduced.		In	situations	when	collaterals	do	not	form,	or	where	the	collaterals	are	insufficient,	ischemia	occurs	as	the	metabolic	demand	is	larger	than	the	blood	supply.	In	cases	of	severe	acute	ischemia,	a	myocardial	infarction	may	 develop.	 The	 infarction	 size	 is	 determined	 by	 the	 muscle	 area	supplied	 by	 the	 occluded	 or	 partly	 occluded	 vessel(s)	 and	 the	preexistence	of	collaterals.		
 
 
 
 
Figure 3. Mechanisms behind ischemia leading to acute coronary 
syndrome. 
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Evaluation of coronary artery function 
Exercise electrocardiogram (ECG) Exercise	 ECG	 is	 a	 well	 validated	 method	 to	 evaluate	 the	 presence	 of	myocardial	 ischemia,	 predict	 prognosis	 of	 coronary	 heart	 disease,	 and	individual	 functional	 capacity	 (35).	 Exercise	 ECG	 detects	 ischemia	indirectly	by	recognizing	the	mismatch	in	metabolic	demand	and	blood	supply,	 and	 therefore	 it	 is	 a	 blunter	 technique	 than	 MPS	 or	echocardiography,	especially	regarding	low	grade	ischemia	(36).		Good	 clinical	 judgment	 regarding	 which	 patients	 that	 are	 suitable	 for	exercise	 provocation	 is	 needed.	 Patients	 with	 unstable	 angina,	 strong	suspicion	 of	 significant	 left	 main	 artery	 stenosis,	 aortic	 dissection	 or	advanced	aortic	valve	stenosis	are	often	not	suitable	due	to	increased	risk	of	complications	during	exercise	(37).	
Echocardiography  Ultrasound	allows	non-invasive	visualization	of	the	working	heart	and	its	valves.	In	patients	with	suspected	myocardial	ischemia,	the	examiner	can	observe	 the	 right	 and	 left	 ventricle,	 thereby	 assessing	 all	 myocardial	segments.	 In	patients	with	ongoing	 ischemia,	 there	may	be	visible	wall	motion	disturbance,	hypokinesia	or	 akinesia,	 in	one	or	more	 segments	corresponding	to	the	affected	coronary	artery.	However,	mild	 ischemia	may	 not	 affect	wall	motion	 at	 rest	 (38).	 Therefore,	 a	 stress	 test	 using	adenosine	 or	 dipyridamole	 infusion	 can	 be	 used	 to	 detect	 ischemia.	During	the	stress	test,	reversible	wall	motion	defects	may	be	detected.	A	positive	 stress	 test	 correlates	well	with	 coronary	artery	disease	and	 is	associated	 with	 an	 increased	 risk	 of	 future	 acute	 coronary	 syndrome	(ACS)	(38-40).		
Myocardial perfusion scintigraphy MPS	 is	 a	 nuclear	 medicine	 imaging	 technique	 regarded	 as	 the	 gold	standard	 in	 evaluating	 suspected	myocardial	 ischemia	 in	patients	with	angina	pectoris	and/or	dyspnea.	MPS	 is	more	cost	effective	 than	other	
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diagnostic	modalities	and	has	higher	predictive	value	than	exercise	ECG	(41).		
	
Figure 4. MPS measurements. Above, at rest; below after stress 
provocation. 
The	 objective	 of	 MPS	 is	 to	 visualize	 myocardial	 blood	 perfusion	 and	metabolic	 dependent	 distribution	 of	 a	 radioactive	 tracer	 (gamma-emitting	 radioisotope	 (42).	 This	 enables	 evaluation	 of	 perfusion	 and	myocardium	 viability	 at	 rest,	 and	 after	 exercise	 or	 pharmacologically	induced	 stress	 (adenosine	 or	 dobutamine).	 During	 rest	 a	 healthy	myocardium	 is	 evenly	 perfused	 and	 the	 tracer	 uniformly	 distributed.	Previously	infarcted	areas	are	seen	as	less	perfused	and	appear	darker	on	the	 images.	 After	 stress	 provocation,	 the	 myocardium	 supplied	 by	diseased	 vessels	 receives	 reduced	 blood	 flow	 compared	 to	 the	surrounding	myocardium.	Comparing	stress	images	to	resting	conditions	detects	 malperfusion.	 Since	 MPS	 is	 based	 on	 relative	 perfusion	measurements,	 it	 has	 less	 prognostic	 value	 in	 a	 balanced	 three	 vessel	disease	and	in	global	microvascular	dysfunction,	as	the	perfusion	defects	will	 be	 more	 evenly	 distributed.	 	 MPS	 may	 detect	 prior	 infarction,	reversible	ischemia	and	viable	myocardium.	It	is	also	a	reliable	method	to	predict	 future	events	 (43)	and	 thereby	guide	 in	decisions	 regarding	revascularization	(44,	45).	
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Coronary angiography If	the	suspicion	of	relevant	ischemia	is	high,	and	in	case	of	ACS,	invasive	coronary	 artery	 diagnostics	 by	 coronary	 angiogram	 is	 often	 indicated	(46).	Via	access	through	either	the	radial	or	femoral	artery,	intracoronary	injection	 of	 contrast	 efficiently	 diagnoses	 lumen	 narrowing	atherosclerosis	 in	 the	epicardial	vessels.	Endothelial	dysfunction	 is	not	detected	 by	 coronary	 angiography	 (47)	 and	 may	 occur	 even	 if	 the	epicardial	vessels	appear	normal.	Coronary	angiography	involves	iodine	contrast	 exposure,	 which	 can	 cause	 allergic	 reactions.	 It	 is	 also	nephrotoxic,	and	may	cause	kidney	failure	in	frail	patients.	As	all	invasive	procedures,	 coronary	 angiography	 has	 a	 risk	 of	 complications,	 mainly	hemorrhagic,	but	coronary	dissections	and	perforations	may	also	occur.		
Figure 5. Normal coronary angiogram of the left coronary artery. 
Non-invasive coronary flow measurements The	 coronary	 arteries	 can	 be	 visualized	 and	 the	 coronary	 blood	 flow	velocity	 (CFV)	 measured	 non-invasively	 using	 transthoracic	 color	Doppler	echocardiography	(TDE)(48,	49).	The	color	Doppler	is	capable	of	reliable	velocity	measurements	of	selected	vessel	segments,	both	at	rest	and	during	hyperemia,	e.g.	induced	by	adenosine	(50-52).		Baseline	measurements	at	rest	in	middle	to	distal	LAD	is	made	in	a	2-3	chamber	view,	using	3.5	MHz	pulsed	Doppler.	Visualization	of	the	vessel	
Non-invasive	assessment	of	coronary	flow	velocity	
	10	
is	done	by	color	Doppler.	The	mean	coronary	flow	velocity	at	baseline	and	during	hyperemia	is	measured	by	manually	tracing	the	diastolic	Doppler	flow	 signals,	 Fig	 3.	 To	 obtain	 a	 measurement	 of	 the	 coronary	 artery	function,	coronary	flow	velocity	reserve	(CFVR)	is	calculated,	i.e.	the	ratio	between	hyperemic	mean	velocity	and	basal	mean	velocity	(53).		
Figure 6. LAD visualized by color Doppler. 
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Coronary flow velocity reserveDuring	 hyperemia,	 coronary	 blood	 flow	 increases	 in	 healthy	 coronary	arteries.	The	extent	of	the	increase	is	called	coronary	flow	reserve	(CFR).	CFR	is	generally	considered	a	volumetric	measurement,	i.e.	the	arteries	ability	to	increase	blood	supply	to	the	working	heart.	It	is	calculated	as	the	 ratio	 between	 blood	 volume	 per	minute	 at	work	 divided	 by	 blood	volume	per	minute	at	rest.	To	calculate	the	blood	volume	per	minute,	the	diameter	of	the	artery	and	the	velocity	of	the	blood	flow	must	be	known.		When	TDE	is	used	to	evaluate	coronary	function,	it	is	possible	to	measure	velocities,	but	not	possible	to	evaluate	the	diameter	of	the	distal	vessels.	The	epicardial	vessels	are	assumed	to	be	unaffected	by	administration	of	adenosine	since	the	dilatation	caused	by	adenosine	occurs	further	down	the	arterial	tree	in	the	resistance	vessels	(54).	If	the	diameter	of	the	vessel	remains	 unchanged	 between	 rest	 and	 adenosine-induced	 stress	measurements,	 the	only	changing	variable	 in	 the	equation	 is	 the	blood	flow	 velocity.	 Consequently,	 CFVR	 is	 comparable	 to	 the	 volumetric	coronary	flow	reserve.		
	
Figure 7. Measurements of coronary flow velocity. Left; at baseline, 
Right; during hyperemia induced by adenosine. 
R Hyp
Non-invasive	assessment	of	coronary	flow	velocity	
	12	
Non-invasive	CFVR	is	a	well	validated	method	to	assess	coronary	artery	function.		When	compared	to	invasively	measured	CFVR,	the	non-invasive	CFVR	measurements	correlate	well	 (53,	55).	The	CFVR	 in	mid	 to	distal	LAD	measured	 by	 TDE	 gives	 prognostic	 information	 to	 predict	 future	cardiovascular	events	(49,	56),	and	a	CFVR	≤2	have	been	used	to	identify	patients	 with	 increased	 risk	 of	 cardiovascular	 events.	 CFVR	 as	 a	complement	 to	 stress	 TDE	 evaluated	 wall	 motion	 defect	 adds	 further	prognostic	value	regarding	CV	events	(57).	CFVR	is	a	sensitive	method	to	detect	reduced	coronary	flow	reserve	not	only	caused	by	epicardial	stenosis,	but	also	endothelial	dysfunction,	and	reduced	flow	due	to	increased	blood	viscosity.	This	makes	it	a	valuable	tool	 also	 in	 patients	 with	 persistent	 chest	 pain	 but	 normal	 coronary	angiography	(56).			 	
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Study objectives As	previously	 stated,	 CFVR	quantifies	 coronary	microvascular	 function	and	is	associated	with	the	risk	of	future	cardiovascular	events	in	different	subgroups	of	coronary	artery	disease	patients.	Mean	CFV	at	baseline	and	during	 maximum	 hyperemia	 are	 used	 to	 calculate	 CFVR.	 Adenosine	provocation	is	used	to	induce	hyperemia	but	it	is	unknown	if	adenosine	causes	 maximal	 hyperemia,	 since	 adenosine	 mainly	 acts	 on	 small	resistance	vessels.		It	is	possible	that	other	vasodilators,	acting	on	other	vessels,	 such	 as	 the	 epicardial	 vessels,	 alone	 or	 in	 combination	 with	adenosine,	would	induce	an	even	higher	level	of	hyperemia.	This	would	be	 important	 if	 CFVR	 should	 be	 compared	 to	 volumetric	 CFR	measurements.	 One	 vasodilator	mainly	 acting	 on	 epicardial	 arteries	 is	nitroglycerine.	 In	 study	 I,	 we	 hypothesized	 that	 pre-treatment	 with	nitroglycerine	 before	 adenosine	 provocation	 in	 CFVR	 measurements	would	enhance	the	hyperemia	further	in	comparison	to	adenosine	alone.	To	test	this	hypothesis,	we	included	healthy	volunteers	in	a	prospective	study	where	we	in	addition	to	the	CFVR	measurements	also	assessed	the	effect	 of	 nitroglycerine	 on	 basal	 coronary	 flow	 and	 coronary	 artery	diameter	and	the	reproducibility	of	repeated	CFVR	measurements.		In	 patients	 with	 suspected	 myocardial	 ischemia,	 MPS	 is	 a	 well-established	 diagnostic	 method.	 MPS	 is	 based	 on	 relative	 perfusion	measurements	 and	 most	 likely	 reflects	 only	 the	 degree	 of	 the	 lumen	obstructing	 CAD,	 which	 may	 cause	 heterogeneous	 flow	 distribution	during	exercise	or	pharmacologically	induced	stress.	In	cases	of	balanced	three-vessel	disease	or	global	microvascular	dysfunction,	MPS	will	have	lower	diagnostic	and	prognostic	value.	CFVR	assessed	by	TDE	is	known	to	 reflect	 presence	 of	 macro-,	 as	 well	 as	 microvascular	 disease	 in	 the	coronary	 circulation.	 Thus,	 the	 quantitative	 CFVR	 may	 reflect	 more	aspects	 of	 the	 coronary	 vascular	 status	 and	 thereby	 provide	 an	incremental	value	to	MPS.	In	study	II,	we	aimed	to	evaluate	the	feasibility	of	 adenosine-induced	 CFVR	 in	 a	 patient	 population	 with	 suspected	myocardial	 ischemia	referred	to	MPS	and	hypothesized	that	CFVR	may	convey	additional	prognostic	values	above	MPS	alone.	
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The	aim	of	study	III	was	to	evaluate	whether	CFVR	measured	with	TDE	predicts	 significant	 (>50%	 lumen	 reduction)	 CAD	 in	 patients	 who	underwent	coronary	angiography	in	routine	clinical	practice.	The	patient	population	was	a	 subgroup	of	patients	 from	study	 II.	We	 included	152	patients	investigated	with	both	MPS	and	coronary	angiography	and	123	of	the	patients	also	underwent	CFVR	measurements.		Ticagrelor,	 an	 oral,	 direct-acting,	 reversibly	 binding	 P2Y12	 receptor	antagonist,	 is	used	in	the	treatment	of	patients	with	ACS.	In	the	PLATO	(Platelet	 Inhibition	 and	Patient	Outcomes)	 trial,	 ticagrelor	 significantly	reduced	 the	 incidence	 of	 myocardial	 infarction,	 stroke,	 or	 death	 from	vascular	 causes,	 compared	 with	 standard	 treatment	 with	 clopidogrel	(58).	 In	 the	same	study,	dyspnea	and	asymptomatic	ventricular	pauses	were	 more	 common	 in	 patients	 receiving	 ticagrelor	 than	 in	 those	receiving	 clopidogrel.	 It	 has	 been	 shown	 that	 ticagrelor	 can	 inhibit	cellular	adenosine	uptake,	likely	through	inhibition	of	the	ENT-1	receptor	(59).	 Ticagrelor	 also	 significantly	 and	 dose	 dependently	 augmented	adenosine-mediated	coronary	blood	flow	increases	in	a	dog	model	(59).	These	findings	could	suggest	increased	local	adenosine	levels	in	patients	treated	with	ticagrelor	because	both	dyspnea	and	ventricular	pauses	are	known	effects	of	adenosine	(23).		The	aim	of	study	IV	was	therefore	to	determine	if	ticagrelor,	at	a	clinically	relevant	dose,	can	augment	adenosine-induced	physiological	responses,	i.e.		coronary	flow	velocity	(CFV),	and	dyspnea	in	healthy	human	subjects.	Furthermore,	 we	 assessed	 the	 reproducibility	 of	 flow	 velocity	measurements.	
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2 AIMS 1. To	describe	the	effects	of	sublingual	nitroglycerine	on	coronary	flow	 velocity	 and	 coronary	 flow	 velocity	 reserve	 in	 healthy	subjects	(Study	I).			2. To	evaluate	if	coronary	flow	velocity	and	coronary	flow	velocity	reserve	measurements	are	reproducible	(Study	I,	IV).			3. To	 evaluate	 if	 coronary	 flow	 velocity	 reserve	 adds	 incremental	prognostic	 value	 in	 addition	 to	 scintigraphy	 in	 patients	 with	suspected	myocardial	ischemia	(Study	II).			4. To	 investigate	 the	 relationship	 between	 CFVR	 and	 significant	coronary	stenosis	in	patients	with	suspected	myocardial	ischemia	(Study	III).				5. To	study	the	effect	of	ticagrelor	on	adenosine-induced	coronary	blood	flow	velocity	and	dyspnea	in	healthy	subjects	(Study	IV).			
Non-invasive	assessment	of	coronary	flow	velocity	
	16	
3 PATIENTS AND METHODS 
Study subjects All	studies	were	conducted	in	accordance	with	the	Declaration	of	Helsinki	and	were	approved	by	the	Regional	Ethics	Committee	in	Gothenburg.	All	study	 subjects	 signed	 a	 written	 consent	 form	 after	 oral	 and	 written	information	before	being	included	in	the	studies.	
Table 1. Study subject characteristics. Mean and standard deviation 
or range, or number (%).  
	 Study	I	 Study	II	 Study	III	 Study	IV	
n	 23	 371	 152*	 40	
Age	(years)	 27	±	5.5	 62.2	±	8.7	 64	(48-81)	 18-40	
Female	gender		 8	(35%)	 197	(53%)	 54	(35.5%)	 0	
Study	subjects	 healthy	 patients	 patients	 healthy	
Diabetes	 0	 46	(12%)	 25	(16%)	 0	
Hypertension		 0	 47	(12%)	 84	(55%)	 0	
Hyperlipidemia	 0	 184	(50%)	 104	(68%)	 0	
*123	of	the	patients	were	also	included	in	study	II	
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CFVR measurements All	 CFV	measurements	 were	made	 by	 transthoracic	 echocardiography	using	 the	 Seimens	 Acuson	 platform	 equipped	with	 a	 4V1C	 transducer	with	3.5	MHz	and	1.75	MHz	spectral	Doppler	frequency	(Acuson	Sequoia	512,	 Mountain	 View,	 California).	 Flow	 velocity	 measurements	 were	performed	 both	 at	 rest	 and	 during	 hyperemia	 induced	 by	 adenosine	infusion	 (ITEM	Development	 AB,	 Stockstund,	 Sweden).	 Cine	 loops	 and	Doppler	images	were	stored	and	analyzed	offline	using	Image	Arena	2.9.1	(TomTec	Imaging	systems	GmbH,	Unterschleissheim,	Germany).		In	study	I	and	IV	all	measurements	were	performed	by	the	same	operator	to	 minimize	 user-dependent	 variation.	 All	 measurements	 were	performed	 in	 the	 middle	 to	 distal	 part	 of	 the	 LAD.	 A	 standardization	protocol	 (see	 below)	was	 used	 to	 ensure	 that	 all	 measurements	 were	made	at	the	same	vessel	segment.	 	In	study	II	and	III	all	measurements	were	made	by	the	same	operator.	In	 study	 I,	 II	 and	 III,	 hyperemia	was	 induced	 by	 adenosine	 infusion	 at	140	 µg/kg/min	 and	 the	 highest	 flow	 velocity	 during	 the	 period	 was	registered.	 In	 study	 IV,	 an	 adenosine	 ladder	was	 used	with	 increasing	doses	 of	 adenosine,	 (50,	 80,	 110	 and	 140	µg/kg/min).	 Each	 dose	was	maintained	for	two	minutes	and	during	the	last	1.5	minutes	of	that	time,	the	highest	flow	velocity	Doppler	registration	was	collected.		During	offline	analysis	of	the	collected	measurements,	the	mean	velocity	of	the	highest	measurement	during	hyperemia	was	calculated	in	study	I,	II	and	III.		
Protocol for repeated measurements (study I and IV) In	 order	 to	 minimize	 method	 depending	 variability	 it	 is	 necessary	 to	perform	all	measurements	at	 the	 same	LAD	segment	and	maintain	 the	same	 angle	 between	 artery	 and	 ultrasound	 beam.	 For	 this	 purpose,	 a	guiding	protocol	was	used.	Information	about	body	position	and	surface	anatomy	 regarding	 ultrasound	 probe	 position	 in	 reference	 to	 the	mammillae	and/or	the	processus	xiphodius	was	registered.	In	addition,	Doppler	beam	angle	regarding	the	vessel,	scale,	frequency	and	gate	size	
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were	 registered	 and	 a	 CINE-loop	 of	 the	 vessel	 was	 stored	 for	 future	guidance.		
Study I Twenty-three	healthy	volunteers	were	recruited	to	undergo	non-invasive	CFVR	measurements	on	LAD.	Exclusion	criteria	were	asthma,	which	can	be	 worsened	 by	 adenosine	 exposure,	 and	 systolic	 blood	 pressure	<100mmHg	 at	 rest,	 as	 two	 vasodilators	were	 administered	 during	 the	study.		The	study	subjects	underwent	four	coronary	flow	velocity	measurements	during	two	consecutive	days.	Measurements	were	performed	both	at	rest	(baseline)	and	during	5	minutes	of	adenosine-induced	hyperemia.	Each	day,	two	sets	of	measurements	were	performed	with	a	10-minute	wash-out	period	between	the	recordings.	Before	the	last	measurement	on	study	day	two,	sublingual	nitroglycerine	(0.5mg)	was	administered	to	the	study	subjects	 and	 after	 5	 minutes	 the	 LAD	 diameter	 was	 assessed	 by	ultrasound.	The	 left	main	coronary	artery	was	visualized	 in	a	modified	short	axis	view	at	aortic	root	level.	CINE-loops	of	a	full	cardiac	cycle	were	stored	at	a	frame	rate	of	70	frames/second	for	offline	measurements.	All	measurements	were	performed	as	close	to	the	R-wave	as	possible	and	at	the	same	position	at	baseline	and	after	nitroglycerine	administration.		
Study II and III From	 February	 2006	 to	 November	 2008,	 468	 patients	with	 suspected	myocardial	 ischemia,	 referred	 for	 MPS	 at	 the	 Department	 of	 Clinical	Physiology	 at	 Sahlgrenska	 University	 hospital	 were	 included	 in	 the	CEVENT-study	(coronary	flow	reserve	and	cardiovascular	events).		Of	the	468	patients	initially	included	in	the	study,	371	underwent	both	MPS	and	CFVR	measurements.	All	CFVR	measurements	were	performed	within	a	week	from	the	MPS.		The	 referring	 physician	 had	 full	 clinical	 information	 about	 the	 results	from	 the	 MPS	 investigation	 but	 all	 flow	 measurements	 were	 blinded.	Follow	up	was	performed	by	a	semi-structured	telephone	interview	by	a	nurse	after	one	year,	and	later	through	medical	records	and	registries.	
Ann	Wittfeldt	
	19	
MPS	was	performed	with	a	two-day	protocol	according	to	the	standard	institutional	protocol.	Stress	provocation	by	exercise	or	pharmacological	provocation	was	performed	and	technetium	(99mTc)	administered	and	detected	using	single-photon	emission	computed	tomography	(SPECT).	Images	were	 obtained	 by	 dual-head	 cameras	 displaying	 perfusion	 and	function	of	 the	 left	ventricle.	An	experienced	physician,	with	 the	aid	of	automatically	 software	 generated	 variables,	 determined	 presence	 and	extent	of	myocardial	ischemia.	Severity	of	reversible	ischemia	was	scored	as	no	ischemia	(0),	mild	(score	1),	moderate	(score	2)	or	severe	(score	3)	and	 extent	 of	 ischemia	was	 scored	 as	 non	 (0),	 small	 (<10%,	 score	 1),	medium	 (10-19%,	 score	 2)	 and	 large	 (>19%,	 score	 3).	 No	 signs	 of	ischemia	om	MPS	was	defined	as	both	severity	and	extent	score	=	0.		In	study	II,	the	371	patients	in	the	CEVENT-study	who	underwent	both	complete	MPS	and	CFVR-measurements	were	included.	The	mean	follow-up	 time	 was	 4.5	 years.	 Primary	 endpoint	 was	 major	 acute	 adverse	cardiovascular	 events	 (MACE)	 defined	 as	 myocardial	 infarction,	 acute	revascularization	or	cardiac	death.		Among	the	patients	included	in	the	CEVENT-study,	the	152	patients	that	were	referred	to	invasive	coronary	angiography	by	their	physician	were	included	in	study	III.	Of	these,	123	had	undergone	CFVR	measurements.	The	 coronary	 angiography	 and	 CFVR-measurements	 were	 performed	within	180	days	of	each	other.	Patient	characteristics	and	angiography	results	were	collected	from	SCAAR	(Swedish	Coronary	Angiography	and	Angioplasty	Registry)	which	is	a	part	of	the	SWEDEHEART	registry	(60)	and	from	medical	charts.	Angiography	was	performed	according	to	the	standard	 institutional	 protocol.	 A	 significant	 stenosis	 was	 defined	 as	
³50%	lumen	reduction	in	native	or	stented	arteries,	or	bypass	grafts.	The	CFVR	results	were	related	to	the	angiography	results.		
Study IV 40	healthy	volunteers	were	included	in	a	double-blind	placebo-controlled	crossover	 study.	The	 study	 involved	 two	examination	days	14-21	days	apart.	 Each	 study	 day	 involved	 three	 coronary	 flow	 velocity	measurements	 including	 basal	 measurements	 at	 rest	 and	 during	 an	adenosine-ladder	 with	 four	 increasing	 adenosine	 doses.	 After	
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ticagrelor/placebo	 measurements,	 the	 adenosine	 antagonist,	theophylline,	was	 administered	before	 the	 last	measurement.	 CFV	was	calculated	 as	 the	 area	 under	 the	 CFV	 curve	 (AUC)	 including	 baseline	velocity	and	velocity	during	the	four	adenosine	doses.	
	
Figure 8. Study design of study IV. (A) Study design and (B) the 
procedures performed at visits 1 and 2.  
IV= intravenous; R =randomization. 
All	study	subjects	were	trained	to	use	a	Borg	scale	to	report	any	sensation	of	dyspnea	during	the	measurements.	The	Borg	scale	was	graded	from	0	(no	sensation	of	dyspnea)	to	10	(maximum	sensation	of	dyspnea).		
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Statistics 
Study I Data	 was	 not	 normally	 distributed	 and	 data	 are	 therefore	 presented	 as	median	and	range.	Wilcoxon	matched	paired	test	was	used	to	compare	CFV,	CFVR	and	artery	diameters,	Freidman’s	test	was	used	when	comparing	the	two	 baseline	 measurements	 on	 study	 day	 1	 to	 baseline	 measurement	 on	study	 day	 2.	 A	 two-sided	 p-value	 of	 <0.05	 was	 considered	 statically	significant.	
Study II Continuous	variables	are	presented	as	mean	±SD	and	categorical	variables	as	number	and	percentages.	Distribution	of	data	was	assessed	by	Shapiro-Wilk	test.	 Differences	 between	 groups	 were	 tested	 using	 Student’s	 t-test	 and	differences	 between	 categorical	 categories	 by	 Chi-square	 test.	 A	multivariable	 logistical	 regression	 model	 was	 used	 to	 identify	 factors	independently	associated	with	MACE.	In	this	model	we	included	age,	gender,	smoking,	hyperlipidemia,	hypertension,	diabetes	mellitus,	ejection	fraction,	MPS	 ischemia	and	pharmacological	 anti-ischemic	 treatment.	Kaplan-Meier	survival	curves	for	event-free	survival	were	calculated.	A	two-sided	p-value	of	<0.05	was	considered	statically	significant	and	hazard	ratios	(HR)	were	calculated	with	their	corresponding	95%	confidence	interval	(CI).	
Study III Normal	distribution	was	determined	by	distribution	of	values	on	histogram	and	 by	 using	 Shapiro-Wilk	 test.	 Student’s	 t-test	 was	 used	 to	 compare	continuous	variables,	 and	 chi-square	 test	 for	 categorical	 variables,	 logistic	regression	 adjusted	 for	 propensity	 score	 (PS)	 was	 used	 to	 calculate	 the	likelihood	of	significant	stenosis	on	coronary	angiography.	Tests	for	trends	were	used	to	test	 the	hypothesis	that	CFVR	decreased	with	severity	of	 the	stenoses.	The	Pearson	product-moment	correlation	coefficient	was	used	to	evaluate	the	strength	and	direction	of	the	linear	relationship	between	CFVR	measured	in	different	coronary	arteries	and	CAD.		
Study IV  To	compare	ticagrelor	and	placebo,	the	area	under	the	curve	(AUC)	of	CFV	versus	the	adenosine	dose	was	estimated	by	using	a	mixed-model	analysis	of	variance.	It	included	the	Log	AUC	change	with	ticagrelor	and	placebo	as	the	response	variable.	A	mixed	effects	model	was	used	 to	assess	 the	effect	on	
Non-invasive	assessment	of	coronary	flow	velocity	
	22	
theophylline	 on	 the	 AUC	 of	 CFV	 versus	 adenosine	 dose	 on	 ticagrelor	 and	placebo,	 the	 differences	 in	 baseline	 blood	 flow	 between	 ticagrelor	 and	placebo	before	and	after	infusion	of	theophylline,	and	the	effect	of	ticagrelor	compared	with	placebo	on	the	CFV	response	at	individual	adenosine	doses.	Mixed-model	analysis	of	variance	with	variance	component	estimation	was	used	to	evaluate	the	intra-day	and	inter-day	coefficients	of	variation	(CV%)	and	SD’s	for	the	CFV	and	Borg	scale	results.	Wilcoxon	signed	rank	tests	were	used	for	testing	the	difference	in	Borg	scale	responses.		
Ann	Wittfeldt	
	23	
4 RESULTS 
Effects of nitroglycerine on coronary artery flow 
velocity in healthy volunteers  There	was	a	significant	reduction	of	baseline	coronary	flow	velocity	after	nitroglycerine	 administration,	 p<0.001.	 In	 contrast,	 there	 was	 no	significant	 difference	 in	 hyperemic	 velocities	 before	 and	 after	nitroglycerine	administration,	p=0.53	(Table	2,	measurement	1:1,	1:2,	2:1	vs.	2:2).		
Table 2. Coronary flow velocity during baseline and hyperemia with 
and without sublingual nitroglycerine administration.  
Measurement	 Baseline	velocity	
(cm/s)	
Hyperemia	velocity	
(cm/s)	
Day	1,	measurement	1	(1:1)	 25	(20-31)	 87	(72-93)	
Day	1,	measurement	2	(1:2)	 25	(19-31)	 97	(77-111)	
Day	2,	measurement	1	(2:1)	 27	(19-31)	 93	(75-105)	
Day	2,	measurement	2	(2:2),	
after	nitroglycerine		
17	(15-24)	 90	(68-116)	
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CFVR	 increased	significantly	during	nitroglycerine	administration	 from	3.6	(range	2.8-4.3)	to	5.0	(4.1-6.0),	p=0.002),	Fig	9,	due	to	a	reduction	in	basal	CFV	while	CFV	during	stress	remained	unchanged	(measurement	2:1	vs	2:2),	Table	2.	In	addition,	there	was	a	significant	increase	in	CFVR	when	the	two	measurements	on	day	1	was	compared	(p=0.007),	Fig	9.	A	significant	increase	in	the	diameter	of	the	left	main	coronary	artery	after	nitroglycerine	administration	was	observed	(from	median	3.1	(2.7-3.6)	to	3.8	(3.1-4.3)	mm,	p=0.018).	
Figure 9. Coronary flow velocity reserve (CFVR) at baseline and 
during adenosine-induced hyperemia. NTG=nitroglycerine. *=p<0.05, 
**=p<0.01, ***=p<0.001. 
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CFVR and cardiovascular events  Seventy-six	 of	 the	 371	 patients	 (20.5	%)	 had	 CFVR	 ≤2.0.	 There	was	 a	significant	 difference	 in	 the	 incidence	 of	MACE	 between	 patients	with	CFVR	≤2.0	and	those	with	CFVR	>2.0,	(unadjusted	HR	4.1,	95%	CI	2.67-6.33,	p<0.001),	Table	3	and	Fig	10.	The	difference	remained	statistically	significant	also	in	a	multivariable	model	(HR	3.02	(1.51-6.04,	p=0.002).			
	
Figure 10. Kaplan-Meier estimation of event-free survival in patients 
with CFVR ≤2.0 or CFVR>2.0. 
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Table 3. Cardiovascular events in patients with CFVR≤2.0 or 
CFVR>2.0. (Numbers and %.) 	
	 CFVR≤2.0	
n=76	
CFVR>2.0	
n=295	
p-value	
(Chi-square)	
MACE	 28	(37%)	 32	(11%)	 <0.001	
Cardiovascular	
death		
8	(11%)	 2	(0.7%)	 <0.001	
Myocardial	
infarction	
6	(7.9%)	 11	(3.7%)	 0.121	
Revascularization	 28	(37%)	 42	(14%)	 <0.001	
CFVR=Coronary	flow	velocity	reserve,	MACE=Major	adverse	cardiovascular	
events.		
 
CFVR, MPS and cardiovascular events  Myocardial	ischemia	as	detected	by	MPS	was	present	in	138	of	the	371	patients	 (37.2%).	 Patients	 with	 MPS-detected	 ischemia	 had	 reduced	CFVR	(2.50	±	0.95	vs.	2.80	±	0.91,	p=0.003).	Patients	with	CFVR	≤2	had	higher	 MPS-ischemia	 score	 and	 larger	 semiquantative	 ischemic	 area	compared	to	patients	with	CFVR	>2.0	(1.0	±	1.1	vs.	0.4	±	0.8,	p	<0.001	and	0.9	±	0.9	vs.	0.4	±	0.7,	p	<0.001,	respectively).		In	 Fig	 11,	 the	 cumulative	 incidence	 of	 MACE	 is	 depicted	 in	 different	subgroups	 of	 patients	with	 and	without	 signs	 of	 ischemia	 on	MPS	 and	with	CFVR	≤2.0	or	CFVR	>2.0.	The	unadjusted	hazard	ratios	are	presented	in	Table	4.			 	
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Figure 11. Kaplan-Meier event-free survival in patients with CFR in 
patients with CFVR ≤2.0 or CFVR >2.0 in patients with or without 
signs of ischemia on scintigraphy.  
Table 4. Hazard ratios in different subgroups of patients. 
	 Hazard	
ratio	
95%	
confidence	
interval	
P	value	vs	CFVR	
>2.0/Scint	neg	
CFVR	>2.0/Scint	neg	 1.00	 	 	
CFVR	>2.0/Scint	pos	 2.62	 1.30-5.31	 0.007	
CFVR≤2.0/Scint	neg	 3.72	 1.58-8.77	 0.003	
CFVR≤2.0/Scint	pos	 10.06	 5.13-19.74	 <0.001	
CFVR=Coronary	flow	velocity	reserve	
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CFVR and coronary artery stenoses CFVR	 in	 any	 of	 the	 three	 coronary	 arteries	 predicted	 significant	 CAD	independently	of	anatomical	localization	and	number	of	diseased	arteries	(p<0.001),	as	presented	in	Table	5	and	Fig	13.	Multivariable	regression	analyses	 demonstrated	 that	 low	 CFVR	 in	 LAD,	 LCx	 and	 RCA	 were	independent	predictors	of	significant	CAD.	Patients	with	significant	CAD	hade	lower	CFVR	in	all	three	coronary	arteries,	Fig	13.	CFVR	decreased	with	increasing	severity	of	CAD	in	LAD	and	LCx	but	not	in	RCA.		
Table 5. Coronary flow velocity reserve (CFVR) in patients with and 
without significant coronary artery disease. Mean and standard 
deviation.  
	 All	 No	CAD	 CAD	 p-value	
LAD	 2.50	±1.05	 2.96	±0.90	 2.32	±1.04	 0.002	
LCx	 2.04	±0.66	 2.31	±0.60	 1.92	±0.66	 0.003	
RCA	 2.23	±0.71	 2.62	±0.64	 2.07	±0.68	 <0.001	
Mean	CFVR*		 2.26	±0.65	 2.55	±0.58	 2.07	±0.61	 <0.001	CAD=Coronary	 artery	 disease,	 LAD=Left	 anterior	 descending	 artery;	LCx=circumflex	 artery,	 RCA=Right	 coronary	 artery,	 CFVR=Coronary	 flow	velocity	reserve.	*Calculated	as	the	average	of	all	available	CFVR,	measured	in	two	or	three	coronary	arteries	per	patient.	
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Figure 12. CFVR measurement in LAD and LCx. 		 	
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Figure 13. Box-and-whiskers plot with median (band inside the box) 
and interquartile range (lower and upper box-line) with minimum and 
maximum values (lower and upper whisker respectively) for CFVR s 
in patients without (no CAD) and with (CAD) significant CAD. CFVR 
decreased with increasing severity of CAD measured as numbers of 
coronary arteries with vessel disease.  
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Ticagrelor, CFV and dyspnea  Baseline	CFV	before	adenosine	provocation	was	similar	before	and	after	administration	 of	 ticagrelor	 and	 placebo	 and	 was	 not	 significantly	attenuated	by	theophylline.	The	adenosine-induced	CFV-AUC	increased	15%	 with	 ticagrelor	 versus	 4%	 for	 placebo	 (p=0.008).	 Ticagrelor	increased	 CFV	 significantly	 compared	 to	 placebo	 when	 50	 and	 80	
µg/kg/min	of	adenosine	was	administered.		
 
 
Figure 14. Adenosine-induced mean coronary blood flow velocity 
(CBFV). Symbols are given by pre-placebo (red dashed line, red 
circle), post-placebo (red solid line, red triangle), pre-ticagrelor (blue 
dashed line, blue circle), post-ticagrelor (blue solid line, blue 
triangle). 
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Figure 15. Symbols are given by post-placebo (red solid line, red 
triangle), post-ticagrelor (blue solid line, blue triangle), post–
theophylline-placebo (red dotted line, red diamond), and post–
theophylline-ticagrelor (blue dotted line, blue diamond). 
Theophylline	infusion	significantly	reduced	the	adenosine	induced	CFV-AUC	 in	 both	 study	 groups,	 Fig	 15.	 The	 reduction	was	 not	 significantly	different	in	subjects	receiving	ticagrelor	or	placebo.	Ticagrelor	 significantly	 augmented	 the	 adenosine-induced	 dyspnea	 at	adenosine	doses	of	110	and	140	µg/kg/min	(p<0.05),	while	no	difference	was	 observed	 after	 placebo	 administration.	 When	 the	 Borg	 scale	 was	compared	between	 the	 ticagrelor	 and	placebo	groups,	 the	values	were	significantly	higher	with	ticagrelor	at	adenosine	doses	of	80,	110,	and	140	
µg/kg/min	 (p<0.01).	 Theophylline	 infusion	 significantly	 reduced	 the	adenosine	 induced	dyspnea	 in	both	 treatment	 groups,	 at	 all	 adenosine	doses	(except	50	µg/kg/min	for	placebo;	p	<	0.01),	Fig	16.		
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Figure 16. (A) Adenosine-induced median Borg scale and (B) the 
effect of the adenosine receptor antagonist theophylline. Symbols 
are given by pre-placebo (red dashed line, red circle), post-placebo 
(red solid line, red triangle), pre-ticagrelor (blue dashed line, blue 
circle), post-ticagrelor (blue solid line, blue triangle), post–
theophylline-placebo (red dotted line, red diamond), and post–
theophylline-ticagrelor (blue dotted line, blue diamond).  
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5 DISCUSSION Coronary	 artery	 disease	 may	 occur	 in	 many	 shapes	 and	 forms.	 Some	patients	have	very	typical	symptoms	and	their	way	from	first	symptom	to	diagnosis	and	treatment	is	short	and	straightforward.	For	others,	that	road	may	be	both	long	and	troublesome.	As	a	clinician,	there	are	many	different	diagnostic	 tools	 to	use	but	yet	no	single	method	gives	the	 full	answer	 regarding	 coronary	 artery	 status.	 Coronary	 angiography	 is	excellent	when	 it	 comes	 to	 lumen	 limiting	 stenosis	 in	 larger	 coronary	arteries	but	CAD	is	often	not	restricted	to	those	larger	vessels	alone.	When	smaller	vessels	are	affected	and	causing	the	patient	symptoms,	the	coronary	 angiography	may	 appear	 normal	 but	 the	 patient’s	 symptoms	remain.	This	is	referred	to	as	small	vessel	disease	or	syndrome	X	(47,	61,	62)	For	these	patients,	the	diagnosis	is	more	difficult.	Ischemia	may	not	appear	on	MPS	as	perfusion	is	more	diffusively	distributed	when	many	small	vessels	are	affected.	The	patients	may	not	have	elevated	myocardial	injury	 markers,	 and	 exercise	 ECG	 is	 often	 inconclusive.	 In	 order	 to	diagnose	 coronary	 artery	disease	 in	 these	patients,	 there	 is	 a	 need	 for	further	diagnostic	tools.		
Coronary flow (velocity) reserve Coronary	 flow	 reserve	 is	 a	 composite	 measurement	 of	 both	 coronary	macro-	 and	 microvascular	 status	 (63).	 Coronary	 flow	 reserve,	 either	volumetrically	or	velocity	assessed,	is	a	sensitive	method	to	detect	flow	limiting	coronary	artery	disease	regardless	of	where	it	is	located	(63).	
Figure 17. Mechanisms influencing CFVR. 
Ann	Wittfeldt	
	35	
In	addition	to	epicardial	vessels	without	 lumen	narrowing	stenoses,	an	intact	 endothelium	 is	 needed	 for	 maximal	 coronary	 flow	 reserve	response	(64).	A	functional	endothelium	is	also,	besides	its	vasodilation	function,	 important	 due	 to	 the	 atheroprotective	 and	 thomboprotective	properties	of	the	arterial	vessel	wall	(17,	64).	It	is	likely	the	combination	of	 impaired	 coronary	vasodilation	 in	 response	 to	myocardial	 ischemia,	and	dysfunctional	protective	mechanisms	in	the	vascular	wall,	that	is	the	answer	 to	 why	 patients	 with	 reduced	 coronary	 flow	 reserve	 have	 an	increased	risk	of	cardiovascular	events.		
CFVR, MPS and major cardiovascular events  We	observed	 in	study	II,	 that	 in	patients	with	suspected	CAD,	CFVR	≤2	was	 associated	 with	 approximately	 a	 four-fold	 risk	 of	 cardiovascular	events	during	follow-up,	compared	to	CFVR	>2.0.	This	suggest	that	even	in	 a	 patient	 population	 where	 all	 patents	 have	 some	 symptoms	 of	ischemic	 heart	 disease,	 CFVR	 measurements	 is	 valuable	 for	 risk	stratification	and	to	aid	decision	making	regarding	further	investigations.  Furthermore,	 it	 has	been	 shown	 that	CFVR	 in	 combination	with	 stress	echocardiography	increases	the	prognostic	value	of	the	results	(39,	57).	Another	 aim	of	 study	 II	was	 to	 investigate	 if	 CFVR	provides	 additional	information	 to	 MPS	 in	 a	 heterogeneous	 patient	 group	 with	 suspected	myocardial	 ischemia.	 Not	 surprisingly,	 the	 patients	 with	 no	 signs	 of	ischemia	 on	 MPS	 and	 a	 CFVR	 of	 >2	 had	 the	 lowest	 incidence	 of	cardiovascular	events	during	follow-up	and	the	patients	with	both	MPS	signs	 and	 reduced	 CFVR	 had	 the	 highest.	 When	 considering	 the	 two	remaining	 groups,	 the	 results	 are	 even	more	 interesting.	 The	 patients	with	CFR	>2	and	normal	MPS	the	unadjusted	hazard	ratio	 increased	to	3.73	compared	to	1	in	patients	with	normal	MPS	and	CFVR,	Fig	11	and	Table	4.	This	indicates	that	in	patients	with	normal	MPS,	it	is	possible	to	use	 CFVR	 to	 identify	 patients	 with	 an	 increased	 risk	 of	 future	cardiovascular	events.	It	is	plausible	that	these	patients	to	a	larger	extent	have	small	vessel	disease	compared	to	epicardial	vessel	disease.	Also	in	patients	with	MPS	detected	 ischemia,	 CFVR	 added	 further	 information	regarding	 risk.	 In	 patients	with	 signs	 of	 ischemia	 on	MPS	 and	 normal	CFVR,	the	unadjusted	hazard	ratio	was	2.6	and	in	patients	with	both	MPS	signs	 of	 ischemia	 and	 CFVR	 ≤2	 the	 hazard	 ratio	 was	 over	 10.	 Taken	
Non-invasive	assessment	of	coronary	flow	velocity	
	36	
together	 this	 indicates	 that	 CFVR	 provides	 important	 prognostic	information	in	addition	to	that	which	can	be	achieved	with	MPS	alone	and	that	 CFVR	 can	 help	 in	 risk	 stratification	 of	 patients	 with	 suspected	ischemic	heart	disease	(65).		
CFVR and epicardial stenoses  Lumen	 narrowing	 stenoses	 in	 epicardial	 vessels	 is	 known	 to	 reduce	coronary	 flow	 reserve	 (66).	 In	 study	 III,	 we	 wanted	 to	 investigate	whether	 non-invasive	 CFVR	 could	 detect	 the	 presence	 of	 significant	stenoses	and	if	it	was	possible	to	specifically	identify	in	which	artery	the	stenosis	was	located.	We	observed	that	patients	with	significant	coronary	stenoses	had	reduced	CFVR	compared	to	patients	without	CAD,	as	shown	in	Fig	13	and	Table	5.	Interestingly,	significant	CAD	was	associated	with	reduced	CFVR	in	all	three	coronary	arteries	even	when	only	one	or	two	of	the	arteries	had	significant	CAD.	The	study	also	showed	that	the	more	advanced	CAD,	 the	 lower	 the	CFVR,	Fig	13.	These	 results	 indicate	 thus	that	CFVR	is	a	potential	diagnostic	tool	to	diagnose	significant	epicardial	CAD,	but	that	the	measurements	are	not	specific	regarding	the	location	of	the	 stenoses.	 One	 possible	 explanation	 is	 that	 atherosclerosis	 is	 a	systemic	disease	and	that	it	does	not	only	engage	epicardial	vessels	but	also	 the	 microcirculation	 (67).	 Impaired	 microcirculation	 including	endothelial	 dysfunction,	 may	 occur	 also	 in	 vessels	 without	 epicardial	stenosis	(56).	The	results	of	study	II	and	III	suggest	that	CFVR	measurements	might	be	a	potential	screening	tool	to	decide	which	patients	that	should	be	referred	to	invasive	examination	with	coronary	angiography.	Given	the	prognostic	information	provided	by	CFVR,	it	might	also	assist	prioritization	to	early	invasive	assessment	among	patients	with	suspected	CAD.	Furthermore,	CFVR	can	also	be	used	to	evaluate	treatment	response.	Progressing	CFVR	reduction	 after	 revascularization	 may	 indicate	 non-optimal	 flow	conditions	and	hence	a	need	for	new	evaluation.	
Reproducibility of CFVR measurements  When	CFVR	measurements	are	repeated	on	the	same	patients	at	different	occasions,	 it	 is	of	utmost	 importance	that	any	detected	changes	in	flow	velocities,	 are	 actually	 due	 to	 flow	 velocity	 changes	 and	 not	 simply	
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method	 dependent.	 There	 are	 many	 possible	 mechanisms	 behind	variability.	Basal	flow	is	often	more	challenging	to	assess	than	flow	during	hyperemia	and	can	increase	due	to	e.g.	anxiety,	talking	and	laughing.	To	reduce	emotional	stress,	it	is	vital	that	the	patient	has	rested	before	the	investigation	and	is	well	 informed.	As	study	I	and	IV	involved	repeated	flow	velocity	measurements,	a	specific	protocol	with	the	aim	to	reduce	variation	was	used.		In	 study	 I,	 we	 specifically	 investigated	 intra-	 and	 inter-day	 variability	regarding	 baseline	 and	 hyperemia	 velocity.	 At	 baseline,	 the	reproducibility	 between	 the	 three	 comparable	measurements	 (1:1,	 1:2	and	 2:1)	 was	 satisfactory.	 This	 indicates	 that	 it	 is	 possible	 to	 achieve	reliable	 baseline	 measurements	 also	 when	 the	 investigations	 are	performed	on	different	days.	Furthermore,	during	the	investigation	it	is	sometimes	necessary	to	pause	the	adenosine	infusion.	When	this	occurs,	objective	measurements	such	as	coronary	 flow	velocity,	heart	rate	and	blood	pressure	regain	to	its	baseline	values	within	1-2	minutes	after	the	adenosine	 infusion	 is	 stopped.	 This	 has	 generally	 been	 regarded	 as	 an	indication	 that	 the	 infusion	 can	 be	 restarted	 and	 the	 examination	continued.	It	 is,	however,	unclear	if	these	repeated	adenosine	infusions	interfere	with	the	following	flow	velocity	results.	In	study	I,	we	evaluated	the	effect	of	a	10-minute	washout	period	between	two	subsequent	CFVR	measurements.	 	 The	baseline	measurements	were	not	 affected.	On	 the	other	hand,	the	second	hyperemic	velocity	during	day	1	was	significantly	higher	 than	 the	 first.	 In	 contrast	 there	 was	 no	 significant	 difference	between	the	first	hyperemic	measurements	on	study	day	1	and	study	day	2.	These	results	indicate	that	the	reproducibility	of	hyperemia	values	is	acceptable	after	24h	but	also	that	a	short	pause	may	influence	the	results.	The	present	study	cannot	identify	the	mechanism	behind	the	increase	in	hyperemia	 flow	velocity	 after	 repeated	adenosine	provocation	but	one	might	 speculate	 that	 it	 can	 depend	 on	 upregulation	 of	 adenosine	receptors.	Based	on	these	results	we	have	changed	our	routine	and	now	try	 to	 avoid	 pausing	 the	 adenosine	 infusion	 unless	 patient	 safety	 is	compromised.	
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In	 study	 IV,	 the	 reproducibility	 of	 CFV	was	 studied	 as	 the	 variation	 in	adenosine-induced	 CFV-AUC.	 The	 inter-individual	 variation	 was	 high,	indicating	 that	 coronary	 flow	 velocity	 both	 at	 baseline	 and	 during	hyperemia	 is	 very	 individual	 and	varies	depending	on	 vessel	 diameter	and	the	amount	of	myocardial	mass	supported	by	the	specific	vessel.	This	suggests	that	it	is	difficult	to	compare	flow	velocities	between	individuals.	Changes	in	coronary	flow	must	be	correlated	to	previous	measurements	i.e.	every	study	subject	needs	to	act	as	its	own	control.	When	studying	the	intra-individual	variation	between	the	three	comparable	measurements,	the	 variation	 was	 low,	 indicating	 acceptable	 reproducibility.	 Taken	together,	 the	 results	 in	 study	 I	 and	 IV	 show	 that	 non-invasive	 flow	velocity	 measurements	 is	 a	 stable	 method	 with	 low	 intra-individual	variability	 when	 using	 a	 standardized	 protocol.	 However,	 we	 did	 not	assess	 observer	 dependent	 variability,	 but	 this	 has	 previously	 been	shown	to	be	low	(53,	55).	
	
Figure 18. Interindividual variation in adenosine-induced CFVR-
AUC. Adenosine dose versus mean coronary blood flow velocity 
(CBFV) response pre-placebo (red dashed line, red circle), post-
placebo (red solid line, red triangle), and pre-ticagrelor (blue dashed 
line, blue circle). 
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Effects of nitroglycerine on coronary flow velocity As	 previously	 discussed,	 coronary	 flow	 reserve	 is	 a	 volumetric	measurement	 while	 CFVR	 is	 based	 on	 flow	 velocity	 measurements.	 A	conclusion	 that	 these	 two	 different	 measurement	 techniques	 are	comparable	 is	based	on	the	assumption	that	the	vessel	diameter	of	 the	investigated	 segment	 remains	 unchanged	 during	 the	 examination.	Adenosine	has	minor	dilatational	effects	on	epicardial	arteries	(68,	69)	and	therefore	CFVR@CFR.	However,	during	hyperemia,	 the	shear	stress	on	the	artery	walls	increases	which	may	induce	some	degree	of	dilatation.	Nitroglycerine	 is	 a	 powerful	 vasodilator	 that	mainly	 acts	 on	 epicardial	arteries	 (69).	 In	 study	 I,	 we	 hypothesized	 that	 by	 administrating	sublingual	nitroglycerine	prior	to	baseline	measurement	and	adenosine	provocation,	further	hyperemia	could	be	induced.		After	 the	 nitroglycerine	 was	 administered,	 baseline	 flow	 velocity	decreased	significantly	and	the	diameter	of	the	left	main	coronary	artery	increased,	 Table	 2.	 There	 is	 no	 reason	 to	 suspect	 that	 the	 velocity	reduction	was	caused	by	decreased	volumetric	 flow,	as	 the	myocardial	oxygen	 demand	 was	 unchanged.	 In	 contrast,	 hyperemia	 velocity	 was	unchanged	after	nitroglycerine	administration.	Unchanged	velocity	in	a	vessel	with	larger	diameter	indicates	a	significant	increase	in	volumetric	blood	flow	and	therefor	increased	hyperemia.	This	suggests	strongly	that	adenosine	alone	did	not	induce	maximal	hyperemia.		We	 further	 hypothesized	 that	 by	 dilating	 the	 epicardial	 arteries	 in	advance,	 it	 would	 minimize	 diameter	 changes	 between	 baseline	 and	hyperemia	measurements,	 and	 thereby	 reduce	 the	 difference	 between	velocity	and	volumetric	assessed	flow	reserve.	As	nitroglycerine	dilates	epicardial	vessels	the	vessel	diameter	ought	to	remain	unchanged	during	hyperemia	 induction	 as	 the	 vessel	 is	 already	 dilated	 by	 the	 start	 of	baseline	measurement.	No	 diameter	measurements	were	made	during	adenosine	infusion,	since	it	would	have	prolonged	the	adenosine	infusion	time.	Diameter	evaluation	at	the	artery	segment	where	the	actual	velocity	measurements	 were	 made	 is	 not	 technically	 possible	 as	 the	 vessel	diameter	 is	 too	 small	 to	 be	 visualized	 without	 color	 Doppler	 and	 the	colour	 signal	 is	 not	 precise	 enough	 to	 be	 measured	 with	 acceptable	accuracy.	 Therefore,	 the	 left	 main	 served	 as	 a	 substitute	 regarding	
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dilatation	and	we	assumed	that	dilatation	of	the	left	main	also	indicates	dilatation	of	more	distal	epicardial	vessel	segments	as	the	dilating	drug	was	systemically	administered.	
Effects of ticagrelor on coronary flow velocity and dyspnea  Ticagrelor	is	a	second	generation	oral	reversible	P2Y12	inhibitor	that	was	introduced	2010.	 In	 the	 large	PLATO	 trial,	 ticagrelor	was	 compared	 to	clopidogrel	 in	 patients	with	 ACS	 (58).	 Ticagrelor	 reduced	 significantly	cardiovascular	events	 (cardiovascular	death,	myocardial	 infarction	and	stroke)	 after	 12	 months	 in	 comparison	 to	 clopidogrel.	 Interestingly,	ticagrelor	 reduced	 both	 cardiovascular	 and	 all-cause	 death.	 This	unexpected	large	difference	between	the	platelet	inhibitors	have	raised	a	number	of	questions	regarding	possible	pleiotropic	effects	that	ticagrelor	may	have,	beside	 the	pure	antithrombotic	effect	 (70,	71).	On	 the	other	hand,	 the	 study	patients	 receiving	 ticagrelor	 experienced	dyspnea	 to	 a	higher	degree	than	the	patients	 in	the	clopidogrel	group.	 	Dyspnea	 is	a	well-known	side	effect	of	adenosine.	Furthermore,	both	 in-vivo	and	 in-vitro	studies	 indicate	 that	 ticagrelor,	beside	 the	antiplatelet	effect,	 also	has	 effects	 on	 adenosine.	 Ticagrelor	 inhibits	 adenosine	 uptake	 in	 red	blood	cells,	by	inhibition	of	the	ENT-1	pathway	(71)	which	prolongs	the	otherwise	so	short	half-life	of	adenosine.	By	prolonging	the	half-life	there	might	be	an	accumulation	of	endogenous	adenosine	 in	the	vasculature,	which	subsequently	may	have	a	favorable	dilating	effect	in	patients	with	persisting	myocardial	ischemia.		In	 study	 IV,	 there	was	no	significant	difference	 in	CFV	with	or	without	ticagrelor	at	baseline	measurements.	During	the	adenosine	ladder,	there	was	a	significant	increase	in	CFV	with	ticagrelor	at	the	lower	doses	(50	and	80µg/kg/min)	but	not	at	 the	higher	doses.	After	administration	of	theophylline,	an	adenosine	antagonist,	the	effect	was	diminished	which	confirms	 the	 adenosine	 component	 in	 the	 flow	 velocity	 response	 of	ticagrelor.		A	similar	study	by	Alexopoulos	et	al	used	the	same	adenosine	ladder	in	an	ACS	patient	population	(72).	They	compared	ticagrelor	to	prasugrel	in	NSTEMI	patients	regarding	CFV-AUC	and	report	comparable	results	with	
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ticagrelor	as	in	the	present	study,	indicating	that	the	present	results	also	are	applicable	in	CAD	patients.		The	 increased	 flow	 velocity	 during	 low	 doses	 of	 exogenously	administered	adenosine	are	in	accordance	with	previous	in	vivo	studies	that	 indicated	 an	 accumulation	 of	 adenosine	 by	 ticagrelor	 (59,	 73).	 A	possible	explanation	to	the	lack	of	difference	with	higher	adenosine	doses	is	 that	 maximal	 adenosine-induced	 hyperemia	 was	 reached	 and	 no	further	increase	can	occur.	Considering	the	adenosine	hypothesis	and	the	results	from	study	IV,	one	may	speculate	that	baseline	flow	velocity	may	increase	 in	 patients	 with	 myocardial	 ischemia	 when	 ticagrelor	 is	administered.	This	may	at	least	partly	explain	the	beneficial	results	with	ticagrelor	 in	 the	 PLATO	 trial.	 However,	 in	 Alexopoulos	 et	 al’s	 study	 in	patients	with	CAD,	no	difference	in	baseline	flow	velocity	with	ticagrelor	was	detected	(72).		In	 study	 IV,	 adenosine-induced	 dyspnea	 increased	 significantly	 after	administration	of	ticagrelor	and	was	reduced	after	theophylline	infusion.	Whether	 this	 is	 the	 cause	 of	 the	 intermittent	 dyspnea	 that	 many	 ACS	patients	experience	during	ticagrelor	treatment	remains	to	be	answered.	Adenosine	is	 likely	involved	in	some	way,	but	 it	 is	doubtful	that	even	a	relatively	 large	 local	 endogenous	 adenosine	 production	 in	 an	 ischemic	myocardium	should	generate	an	adenosine	concentration	high	enough	to	induce	systemic	side	effects.		 	
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Limitations   
Study	 I	 was	 performed	 in	 a	 limited	 study	 population.	 No	 sample	 size	calculation	 was	 made	 due	 to	 the	 descriptive	 nature	 of	 the	 study.		Secondly,	the	study	was	performed	in	a	young,	healthy	population.	It	is	unclear	whether	the	results	can	be	applied	on	patients	with	established	CAD.	Finally,	left	main	artery	diameter	was	only	evaluated	in	a	subset	of	the	patients.	A	new	study	with	complete	measurements	in	a	large	number	of	CAD	patients	is	therefore	warranted.		A	 combined	 endpoint	 (MACE)	 was	 necessary	 in	 Study	 II	 due	 to	 the	limited	 study	 population.	 The	 study	 lacks	 statistical	 power	 in	 the	individual	MACE	components.		
In	 study	 III,	 the	main	 study	 limitation	 is	 the	 time	 frame	 between	 the	coronary	 angiography	 and	 the	 CFVR	measurements.	 Accordingly,	 CAD	progress	may	have	occurred	between	the	two	examinations	and	interfere	with	the	results.	There	was	also	a	significant	proportion	of	missing	data	which	was	solved	by	using	a	multiple	imputation	method.	A	larger	study	population	would	have	been	of	value	to	predict	stenosis	on	a	single	vessel	level.	
Study	IV	were	performed	on	a	healthy	male	population.	The	decision	to	only	include	males	was	taken	in	order	to	avoid	potential	coronary	flow	velocity	changes	due	to	hormonal	changes	during	the	menstrual	cycle.	It	would	be	of	value	to	repeat	the	investigation	in	patients	with	CAD.		
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6 SUMMARY 
1. Administration	of	sublingual	nitroglycerine	reduces	baseline	coronary	flow	velocity	and	increases	coronary	flow	velocity	reserve	in	healthy	subjects	(Study	I).		
2. The	reproducibility	of	coronary	flow	velocity	and	coronary	flow	velocity	reserve	measurements	is	acceptable	(Study	I,	IV).	
3. A	reduced	coronary	flow	velocity	reserve	adds	prognostic	value	in	addition	to	scintigraphy	in	patients	with	suspected	myocardial	ischemia	(Study	II).		
4. A	reduced	coronary	flow	velocity	reserve	is	associated	with	significant	coronary	stenoses	in	patients	with	suspected	coronary	artery	disease	(Study	III).		
5. Ticagrelor	augments	adenosine-induced	coronary	blood	flow	velocity	and	dyspnea	in	healthy	subjects	(Study	IV).			
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7 FUTURE PERSPECTIVES Non-invasive	 flow	 velocity	 measurement	 is	 an	 emerging	 method	 to	evaluate	 coronary	 artery	 status.	 The	 method-dependent	 variability	 is	acceptable	to	detect	changes	in	coronary	flow	velocities,	both	at	baseline	and	during	hyperemia,	as	partly	shown	in	the	present	investigation.	As	it	is	 non-invasive,	 involves	 no	 radiation	 and	 no	 iodine	 contrast,	 the	examinations	can	be	repeated	if	a	new	evaluation	is	needed.		The	need	to	further	sharpen	our	diagnostic	tools	in	patients	with	CAD	is	a	 driving	 force	 to	 continue	 the	 development	 of	 flow	 velocity	measurements.	Furthermore,	flow	velocity	may	in	the	future	be	used	also	to	evaluate	the	effect	of	different	medical	and	 interventional	 treatment	options	and	to	individualize	the	therapy	in	patients	with	ischemic	heart	disease.	It	 is	 important	 to	 risk	 stratify	 patients	 with	 suspected	 CAD,	 both	 to	prevent	acute	events,	such	as	myocardial	infarction	and	sudden	cardiac	death,	and	to	prioritize	patients	for	early	invasive	investigations.	We	have	shown,	in	study	II	and	III,	that	low	CFVR	provides	important	information	about	 the	 risk	 of	 future	 cardiovascular	 events	 and	 the	 presence	 of	coronary	stenoses	 in	patients	with	suspected	coronary	 ischemia.	Given	the	 advantages	 of	 CFVR	measurements	 compared	 to	 other	modalities,	one	may	argue	that	CFVR	measurements	should	be	a	standard	method	in	the	examination	of	patients	with	suspected	CAD.	Furthermore,	if	patients	leaving	hospital	 after	 an	ACS	episode	had	 their	CFVR	evaluated	before	discharge	it	would	be	a	useful	tool	to	monitor	treatment	effects	and	for	early	detection	of	progress	in	flow	limiting	CAD.	The	pleiotropic	effects	of	 ticagrelor	are	still	not	 fully	understood.	Flow	velocity	 measurements	 provide	 a	 useful	 tool	 to	 study	 the	 effects	 of	ticagrelor	 and	 other	 drugs	 on	 the	 coronary	 arteries.	 There	 are	 many	exciting	studies	yet	to	be	done.	Long	term	effects	of	platelet	inhibitors	on	coronary	 flow	and	CFVR	 is	not	yet	determined.	There	 is	also	a	need	 to	identify	patients	who	would	be	candidates	for	long-term,	potentially	life	long,	 treatment	 with	 platelet	 inhibitors	 and	 other	 cardio-protective	drugs.	It	is	possible	that	flow	velocity	measurements	can	aid	in	identifying	these	 patients	 by	 determining	 the	 risk	 for	 future	 cardiac	 events	 and	assessing	effects	of	the	treatment.	
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8 SAMMANFATTNING PÅ SVENSKA Ischemisk	 hjärtsjukdom	 är	 en	 folksjukdom	 orsakad	 av	 ateroskleros	(åderförkalkning),	 i	 hjärtats	 kranskärl.	 När	 aterosklerosen	 i	 hjärtats	kärlväggar	ökar	kan	blodkärlet	förträngas	och	hjärtmuskelns	tillflöde	av	blod	begränsas.	Patienterna	riskerar	då	att	utveckla	symptom	i	form	av	angina	 pectoris	 (kärlkramp),	 hjärtinfarkt	 och	 i	 värsta	 fall	 plötslig	hjärtdöd.	Det	är	därför	viktigt	att	tidigt	upptäcka	om	patienter	har	sjuka	kranskärl.	 Standardundersökningen	 vid	 stark	 misstanke	 är	kranskärlsröntgen,	koronarangiografi,	där	man	 injicerar	kontrastmedel	direkt	 i	 kranskärlen	 via	 en	 kateter	 som	 läggs	 in	 i	 en	 pulsåder	 vid	handleden	 eller	 i	 ljumsken.	 Hos	 patienter	 med	 svagare	 misstanke	genomförs	ofta	en	scintigrafi-undersökning	där	man	injicerar	radioaktiva	substanser	 som	 samlas	 i	 hjärtat.	 Ett	 annat	 nyare	 sätt	 att	 upptäcka	sjukdomen	är	att	utvärdera	kranskärlsfunktionen	med	hjälp	av	ultraljud.	Fördelen	med	ultraljudsundersökning	av	kranskärlen	är	att	metoden	är	icke-invasiv,	dvs	man	behöver	inte	föra	in	katetrar	till	hjärtat	eller	injicera	radioaktiva	 substanser,	 vilket	 annars	 kan	 behövas	 för	 att	 bedöma	kranskärlen.	Med	ultraljudet	mäter	man	blodets	hastighet	genom	ett	av	hjärtats	större	kranskärl,	dels	 i	vila	och	dels	under	maximalt	blodflöde,	vilket	induceras	genom	att	en	kärlvidgande	substans,	adenosin,	injiceras	i	blodbanan.	Genom	att	beräkna	kvoten	mellan	dessa	två	hastigheter	får	man	ett	mått	på	kranskärlets	funktion,	den	s	k	kranskärlsflödes-reserven	(CFVR).			I	det	första	delarbetet	undersöktes	på	23	friska	frivilliga	försökspersoner	om	 adenosin	 ger	 maximalt	 blodflöde	 eller	 om	 tillägg	 av	 en	 annat	kärlvidgande	 ämne,	 nitroglycerin,	 också	 påverkar	 CFVR.	 Vidare	utvärderades	 reproducerbarheten	 av	 undersökningen,	 dvs	 variationen	av	CFVR	vid	upprepade	mätningar.	Vi	fann	att	flödeshastigheten	i	vila	blir	lägre	 efter	 nitroglycerintillförsel	 och	 att	 CFVR	 därmed	 ökar,	 men	noterade	 ingen	 påverkan	 på	 den	 maximala	 flödeshastigheten.	Reproducerbarheten	 var	 i	 huvudsak	 god	 men	 den	 maximala	flödeshastigheten	 under	 adenosin-infusion	 kan	 påverkas	 om	 tiden	mellan	undersökningarna	är	kort.				
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I	det	andra	delarbetet	undersöktes	vilken	information	CFVR-mätningen	ger	 avseende	 risken	 för	 kardiovaskulära	 händelser,	 såsom	hjärtinfarkt	och	 plötslig	 död.	 Vi	 studerade	 371	 patienter	 med	 misstänkt	kranskärlssjukdom	under	en	femårsperiod	efter	undersökningen.	Vidare	studerades	 om	 tillägg	 av	 CFVR	 till	 scintigrafiresultaten	 ger	 mer	information	 än	 vad	 som	 erhålls	 med	 bara	 scintigrafi,	 som	 är	 en	standardundersökning	 vid	 misstänkt	 kranskärlssjukdom.	 Vi	 fann	 att	risken	 för	 kardiovaskulära	 händelser	 var	 cirka	 fyra	 gånger	 högre	 hos	patienter	med	onormalt	låg	CFVR	än	hos	patienter	med	normal	CFVR.	Vi	fann	 också	 att	 kombinationen	 av	 scintigrafi	 och	 CFVR	 ger	 mer	information	om	risken	för	framtida	händelser	än	endast	scintigrafi.		I	det	tredje	delarbetet	undersöktes	om	CFVR-mätningar	kan	användas	för	att	diagnosticera	flödesbegränsande	kranskärlsförträngningar.	I	studien	inkluderades	123	patienter	som	både	undersökte	kranskärlen	med	CFVR	och	 med	 invasiv	 koronarangiografi.	 Resultaten	 visade	 att	 CFVR-resultaten	 var	 oberoende	 associerade	 med	 täta	 förträngningar	 i	kranskärlen,	 dvs	 risken	 för	 att	 ha	 täta	 förträngningar	 var	 stor	 hos	patienter	 med	 låg	 CFVR.	 Resultaten	 från	 delarbete	 II	 och	 III	 visar	sammantaget	 att	 rutinmässiga	 CFVR	 mätningar	 skulle	 kunna	 bli	 ett	värdefullt	 tillskott	 i	 handläggningen	 av	 patienter	 med	 misstänkt	kranskärlssjukdom.	I	 det	 fjärde	 delarbetet	 användes	 flödesmätningar	med	 ultraljud	 för	 att	studera	 effekten	 av	 ticagrelor	 på	 adenosin-inducerad	 flödeshastighet	 i	kranskärlen	och	på	andfåddhet	på	40	friska	försökspersoner.	Ticagrelor	är	 ett	 relativt	 nytt	 trombocythämmande	 läkemedel	 som	 ges	 vid	 akuta	typer	av	ischemisk	hjärtsjukdom.	Tidigare	studier	har	visat	att	ticagrelor	minskar	 risken	 att	 återinsjukna	 i	 akut	 hjärtsjukdom	 men	 att	 en	 del	patienter	 kan	 drabbas	 av	 biverkan	 i	 form	 av	 plötsliga	 episoder	 av	andfåddhet.	 Det	 är	 svårt	 att	 förklara	 hur	 den	 trombocythämmande	effekten	av	ticagrelor	skulle	kunna	ge	andfåddhet	men	studier	har	också	visat	 att	 ticagrelor	 verkar	 hämma	 adenosin-upptaget	 i	 blodet,	 vilket	förlänger	adenosins	tid	i	blodbanan,	vilket	i	sin	tur	skulle	kunna	förklara	andfåddheten	 och	 möjligen	 den	 minskade	 risken	 för	 hjärtsjukdomar.	Resultaten	i	det	fjärde	delarbetet	visade	att	ticagrelor	i	kombination	med	adenosin	ger	ökat	kranskärlsflöde	jämfört	med	endast	adenosin	och	att	
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ticagrelor	även	ökade	den	adenosin-orsakade	andfåddheten.	Resultaten	stöder	därför	att	adenosin	är	involverad	i	de	hjärtskyddande	effekterna	av	ticagrelor.		
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